Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15830146 | 1.00 | KDM4E (0.54) | KDM4EATMHTR2CHSD11B1SIGMAR1 | |
| SCHEMBL13416028 | 0.89 | KDM4E (0.49) | KDM4EHTR2CKCNH2 | |
| SCHEMBL13085385 | 0.89 | HTR2C (0.58) | HTR2CSIGMAR1OPRL1KCNH2 | |
| SCHEMBL2269413 | 0.86 | KDM4E (0.49) | KDM4EATMHTR2CSIGMAR1 | |
| SCHEMBL15834214 | 0.84 | HTR2C (0.52) | HTR2C | |
| SCHEMBL24519848 | 0.81 | KDM4E (0.54) | KDM4EATMSIGMAR1 | |
| SCHEMBL8088234 | 0.80 | KDM4E (0.53) | KDM4EATMHTR2CSIGMAR1 | |
| SCHEMBL13416055 | 0.80 | KDM4E (0.53) | KDM4EATMSIGMAR1 | |
| SCHEMBL13698235 | 0.80 | KDM4E (0.56) | KDM4EATM | |
| SCHEMBL11541762 | 0.79 | KDM4E (0.51) | KDM4EATMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-08-15 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, G6PC1 | KDM4E 2000/4885ATM 1795/4885HTR2C 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.